If you have been reading about counterion and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
=== Episil - oral mucositis pain === Oral mucositis is a severe side-effect of chemotherapy or radiotherapy during cancer treatment, and is often a dose-limiting factor in treatment. episil is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity. It has been demonstrated in several clinical trials that episil gives an immediate and significant reduction of pain. This analgesic effect was maintained over at least 8 hours following administration. The treatment was reported to be safe and well tolerated. The product is registered as a medical device in a wide range of countries, including the European Union and the United States.
== Metabolism == The following section describes the ADME (absorption, distribution, metabolism and excretion) of α-bungarotoxin. There is limited information available on the pharmacokinetics of this neurotoxin. More research is needed to be able to fully understand the metabolism of this neurotoxin inside the body. Absorption: α-bungarotoxin enters the body after envenomation into the bloodstream at the bite site. Through the venom, a mixture of proteins and different molecules enter the body. Distribution: Once in the bloodstream, α-bungarotoxin circulates throughout the body. Its distribution may be influenced by factors such as blood flow, tissue permeability, and the presence of binding proteins. Additionally, knowing it binds to nAChRs, it can be predicted where the neurotoxin would be present: neuromuscular junctions, autonomic ganglia, peripheral nerves, and adrenal medulla. One of the main locations would be also the central nervous system (CNS), including the brain. Specific regions such as the hippocampus, cortex, and basal ganglia contain these receptors. Metabolism: The metabolic pathways of this neurotoxins have not been fully understood yet, however, it is thought to be metabolised in the liver. Researching venom metabolism is challenging due to the multiple components present in it. Toxins that are not bound may undergo elimination through opsonization by the reticuloendothelial system, mainly involving the liver and kidneys, or they may undergo degradation through cellular internalization facilitated by lysosomes.
== Taxonomy == The name Artocarpus is derived from the Greek words artos ("bread") and karpos ("fruit"). This name was coined by Johann Reinhold Forster and J. Georg Adam Forster, a father-and-son team of botanists aboard HMS Resolution on James Cook's second voyage; they used it in their book Characteres generum plantarum. It is maintained as a conserved name. Although fossils of Artocarpus have been reported from as early as the Late Cretaceous, these fossils generally that lack key diagnostic characters such as that could definitively place them in the genus. The last common ancestor of all living Artocarpus likely originated in the vicinity of Borneo, from which Artocarpus dispersed elsewhere in Asia and Oceania.
Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.
Sources: en.wikipedia.org
Simpson argues of the ANC that, "the appeal of its confrontational policies – and above all its armed struggle – meant it was accorded the mantle of symbolic leadership by the youths spearheading the fighting". On some accounts, many sought to further the uprising precisely (or partly) in order to respond to Tambo's call to make the townships ungovernable.
messenger RNA (mRNA) Any of a class of single-stranded RNA molecules which function as molecular messengers, carrying sequence information encoded in the DNA genome to the ribosomes where protein synthesis occurs. The primary products of transcription, mRNAs are synthesized by RNA polymerase, which builds a chain of ribonucleotides that complement the deoxyribonucleotides of a DNA template; in this way, the DNA sequence of a protein-coding gene is effectively preserved in the raw transcript, which is subsequently processed into a mature mRNA by a series of post-transcriptional modifications.
Rural tourism, focusing on getting visitors acquainted with local folklore and customs, has become an important alternative, and is targeted to promote such sites as Bran and its Dracula's Castle, the painted churches of northern Moldavia, and the wooden churches of Maramureș, or the villages with fortified churches in Transylvania. The Via Transilvanica long-distance hiking and cycling trail, which crosses 10 counties in the Transylvania, Banat and Bukovina regions of the country further promotes rural slow tourism. Other important itineraries include Via Mariae, EuroVelo 6 and 13, etc. In 2014, Romania had 32,500 companies active in the hotel and restaurant industry, with a total turnover of €2.6 billion. More than 1.9 million foreign tourists visited Romania in 2014, 12% more than in 2013. According to the country's National Statistics Institute, some 77% came from Europe (particularly from Germany, Italy, and France), 12% from Asia, and less than 7% from North America.
Sources: en.wikipedia.org
== History == In 1982, Dan Duchaine formulated the first pre-workout, called Ultimate Orange, in Venice, California. Ultimate Orange was commonly used among bodybuilders. Between the late 1990s and early 2000s, consumers alleged that an active ingredient in Ultimate Orange, called Ephedra, caused high blood pressure, strokes, seizures, cardiac arrhythmia, and heart attacks. The risk of using Ephedra gave rise to creatine. Creatine is a supplement that was used by a lot of athletes in the 1992 Olympics where it gained most of its popularity from. Creatine was considered a form of pre-workout in the late 1990s until the early 2000s where it was then later used with a mixture of other supplements. Creatine was negatively received when it was first introduced to the public until the last decade where it is now one of the most used supplements. In the early 2000s, supplement companies created more potent forms of pre-workout that caused the blood flow in muscles to increase temporarily, giving lifters a better "pump." These more potent supplements are called Arginine AKG, Arginine Malate, and Citrulline. In 2005, chemist Patrick Arnold formulated a pre-workout which contained a new ingredient called DMAA (dimethylamylamine). The product Jack3d gained notoriety for its potency, but its high concentrations of DMAA were suspected of causing shortness of breath, chest pain, and an elevated risk of heart attacks. Jack3d was banned in 2012 by the FDA.
== Stock exchange listing and later history == Mondobiotech's common shares began trading on the SIX Swiss Exchange on 26 August 2009 under the symbol RARE. The first day's closing price was CHF 392. SIX records a market capitalization of approximately CHF 490 million in its historical listing data. In its account of the listing, the Swiss business magazine BILANZ reported an implied value of approximately CHF 2.6 billion for the entire company at the first-day closing price, noting that only a small number of shares had traded that day. No new shares were issued as part of the initial listing. BILANZ reported in 2011 that the company had accumulated losses and had not yet brought a medicine to market. Mondobiotech changed its name to THERAMetrics in June 2013 and completed its combination with Pierrel Research International in September 2013. THERAMetrics subsequently combined with Relief Therapeutics SA and changed its corporate name to Relief Therapeutics Holding AG in July 2016.
=== Sunblock and sunscreen === Sunblock and sunscreen are different important skin-care products though both offer full protection from the sun. Sunblock—Sunblock is opaque and stronger than sunscreen, since it is able to block most of the UVA/UVB rays and radiation from the sun, and does not need to be reapplied several times in a day. Titanium dioxide and zinc oxide are two of the important ingredients in sunblock. Sunscreen—Sunscreen is more transparent once applied to the skin and also has the ability to protect against UVA/UVB rays, although the sunscreen's ingredients have the ability to break down at a faster rate once exposed to sunlight, and some of the radiation is able to penetrate to the skin. In order for sunscreen to be more effective it is necessary to consistently reapply and use one with a higher sun protection factor.
== Target == ω-Grammotoxin SIA is a 36 amino acid residue protein toxin from spider venom that inhibits P, Q, and N-type voltage-gated calcium channels in neurons. It binds to the channels with high affinity (if closed). It also binds to potassium channels but with lower affinity than to the calcium channels. The toxin binding site has high affinity when channels are in closed states and low affinity when channels are activated. (4)
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.